BUZZ-Cyclo Therapeutics jumps on prelim late-stage data of genetic disorder drug

Shares of drug developer Cyclo Therapeutics CYTH.O rise ~40% to $1.08 - set for biggest single-day pct jump in nearly 4 years, if gains hold

Preliminary data from a late-stage study shows 87% of patients under the age of 3 with a rare genetic disorder saw stabilization or improvement in disease progression after 24 weeks when treated with co's drug, trappsol cyclo - CYTH

Co evaluating drug for treatment of Niemann-Pick Disease Type C1, a condition where cholesterol builds up in cells, causing damage and potentially premature death

Co says it plans to release the trial data in H1 2025

More than 64 mln shares traded, 1157 times their 25-day moving avg

CYTH shares fell 64.5% in 2024